A US District Court dismisses antitrust claims on reverse payment on the pharma market (Androgel Antitrust Litigation)

FTC Gets Shut Down – Once Again – In Its Bid To Change How Courts View Reverse Payment Settlements* As previously reported on this blog, in January 2009, the Federal Trade Commission launched its latest challenge to the legality of reverse payment settlements in the pharmaceutical industry, this time directed at two settlements involving the brand-name drug AndroGel. A full year later, on February 22, 2010, the United States District Court for the Northern District of Georgia dismissed the FTC’s complaint for failure to state a claim. In re: AndroGel Antitrust Litig. (No. II), 1:09-md-02084-TWT, slip op. (N.D. Ga. Feb. 22, 2010). This is the latest in a series of setbacks for the FTC in its long-standing bid to persuade courts that reverse payment settlements are anticompetitive and

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Sheppard Mullin (Los Angeles)

Quotation

Helen Cho Eckert, A US District Court dismisses antitrust claims on reverse payment on the pharma market (Androgel Antitrust Litigation), 22 February 2010, e-Competitions Bulletin February 2010, Art. N° 66634

Visites 25

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues